Lack of Pharmacokinetic Interaction for ISIS 113715, a 2???-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone-Reference-Cited by-同舟云学术

Lack of Pharmacokinetic Interaction for ISIS 113715, a 2???-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone

Published:2006 Issue:8 Volume:45 Page:789-801
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clinical Pharmacokinetics

Author:

Geary Richard S,Bradley JoAnn D,Watanabe Tanya,Kwon Younggil,Wedel Mark,van Lier Jan J,vanVliet Andr?? A

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference25 articles.

1. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence

2. Protein-tyrosine Phosphatase 1B Is a Negative Regulator of Insulin- and Insulin-like Growth Factor-I-stimulated Signaling

3. Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in Lipogenesis

4. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice

5. PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-α PHOSPHOROTHIOATE 2′-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics;Frontiers in Cardiovascular Medicine;2024-08-22

2. Therapeutic Potential of FXI Inhibitors: Hype or Hope?;Drugs;2024-07-29

3. Pharmacological and clinical appraisal of factor XI inhibitor drugs;European Heart Journal - Cardiovascular Pharmacotherapy;2024-01-09

4. Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling;Expert Opinion on Drug Metabolism & Toxicology;2023-11-18

5. Pharmacokinetics and Absorption, Distribution, Metabolism and Excretion of RGLS4326 in Mouse and Monkey, an Anti–miR-17 Oligonucleotide for the Treatment of Polycystic Kidney Disease;Drug Metabolism and Disposition;2023-08-29